# BioNTech SE: financial statements, quarterly

BNTX · Nasdaq · CIK 1776985 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bntx.md) · [Financials](/companies/bntx/financials.md) · [Filings](/companies/bntx/filings.md) · [Insiders](/companies/bntx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bntx/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2016-12-31) | period not labelled (2017-12-31) | period not labelled (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0001564590-20-014536.md) | [0.2](/filings/0001564590-21-016723.md) | [0.4](/filings/0000950170-22-020213.md) | [0.5](/filings/0001193125-23-079791.md) | [1.2](/filings/0001776985-24-000027.md) | [1.7](/filings/0001776985-25-000013.md) | [13.9](/filings/0001776985-26-000017.md) | [11.7](/filings/0001776985-26-000017.md) | [9.8](/filings/0001776985-26-000017.md) | [7.7](/filings/0001776985-26-000017.md) |
| Current assets | $bn | not reported | not reported | [0.4](/filings/0001564590-20-014536.md) | [0.6](/filings/0001564590-21-016723.md) | [1.7](/filings/0000950170-22-020213.md) | [15.1](/filings/0001193125-23-079791.md) | [21.9](/filings/0001776985-24-000027.md) | [19.5](/filings/0001776985-25-000013.md) | [18.8](/filings/0001776985-26-000017.md) | [16.1](/filings/0001776985-26-000017.md) |
| Total assets | $bn | not reported | not reported | [0.7](/filings/0001564590-20-014536.md) | [0.8](/filings/0001564590-21-016723.md) | [2.3](/filings/0000950170-22-020213.md) | [15.8](/filings/0001193125-23-079791.md) | [23.3](/filings/0001776985-24-000027.md) | [23.0](/filings/0001776985-25-000013.md) | [22.5](/filings/0001776985-26-000017.md) | [22.0](/filings/0001776985-26-000017.md) |
| Current liabilities | $bn | not reported | not reported | [0.1](/filings/0001564590-20-014536.md) | [0.1](/filings/0001564590-21-016723.md) | [0.6](/filings/0000950170-22-020213.md) | [3.5](/filings/0001193125-23-079791.md) | [3.0](/filings/0001776985-24-000027.md) | [2.1](/filings/0001776985-25-000013.md) | [2.5](/filings/0001776985-26-000017.md) | [2.1](/filings/0001776985-26-000017.md) |
| Total liabilities | $bn | not reported | not reported | [0.4](/filings/0001564590-20-014536.md) | [0.3](/filings/0001564590-21-016723.md) | [0.9](/filings/0000950170-22-020213.md) | [3.9](/filings/0001193125-23-079791.md) | [3.2](/filings/0001776985-24-000027.md) | [2.8](/filings/0001776985-25-000013.md) | [3.1](/filings/0001776985-26-000017.md) | [2.8](/filings/0001776985-26-000017.md) |
| Shareholders' equity | $bn | [0.0](/filings/0001564590-20-014536.md) | [(0.0)](/filings/0001564590-21-016723.md) | [0.3](/filings/0001564590-20-014536.md) | [0.5](/filings/0001564590-20-014536.md) | [1.4](/filings/0001776985-24-000027.md) | [11.9](/filings/0001776985-25-000013.md) | [20.1](/filings/0001776985-26-000017.md) | [20.2](/filings/0001776985-26-000017.md) | [19.4](/filings/0001776985-26-000017.md) | [19.2](/filings/0001776985-26-000017.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 251,204,366 at 2026-03-27, from the cover of the [20-F/A filed 2026-07-30](/filings/0001776985-26-000049.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.